biotech / news / / City A.M.
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics, today reported financial results for the first quarter of 2026.
Roche's prasinezumab showed a sustained two-year delay in Parkinson's progression over five years in OLE studies.
KEY POINTS
- Novo Nordisk's coramitug received FDA Fast Track designation for ATTR-CM and triggered a $50 million payment to Prothena.
- Prothena's Q1 2026 net income was $32.7 million versus a $60.2 million loss in Q1 2025.
- Prothena lowered 2026 net cash burn guidance to $18–23 million, citing milestone revenue and spending reductions.
- Prothena may receive a $55 million milestone from Bristol Myers Squibb for PRX019 by year-end 2026.
COMPANIES
Summarized by Newsio from City A.M.. How we summarize →